Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Hematopoietic and Lymphatic System Neoplasm 1Breast Neoplasms 1

Interventions

pembrolizumab 223Carboplatin 217Cisplatin 205Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 114Dexamethasone 102Pemetrexed 101Cyclophosphamide 101Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 94Doxorubicin 90Fluorouracil 88Bevacizumab 83Nivolumab 74Leucovorin 73Rituximab 70durvalumab 66Vincristine 66Lenalidomide 64Irinotecan 61Etoposide 61atezolizumab 60Radiation 60130-nm albumin-bound paclitaxel 57Prednisone 56Letrozole 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Bupropion × 1 year × Clear all
NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT03996265 2026-01-15

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

University of Rochester

Phase 3 Active not recruiting
422 enrolled
Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡